TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.
GSK subsidiary, TESARO, Inc., confirms it has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court. This action contends that recent conduct by AnaptysBio is in material breach of the existing license agreement with TESARO regarding the oncology treatment Jemperli (dostarlimab). The breach entitles TESARO to terminate the current license agreement, obtain a perpetual and irrevocable license to dostarlimab, and to reduce the royalties and milestone payments due by TESARO to AnaptysBio by 50%.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.